Crescent Reports Q1 Revenue of $1.04M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Reports Q1 revenue $1.04M, consensus $357,140. "Crescent's execution on the advancement of our pipeline this quarter positions us for meaningful clinical data readouts in 2027 from CR-001, our potentially best-in-class PD-1 x VEGF bispecific antibody, as well as our differentiated ADC programs. The innovative design of our Phase 1/2 ASCEND study of CR-001 enables us to quickly generate comprehensive data for this next generation immuno-oncology backbone both as monotherapy and in combination with standard of care chemotherapy in multiple tumor types, and we're also working with our partner, Kelun-Biotech, to deliver ADC combination data," said Joshua Brumm, chief executive officer of Crescent. "We are pleased that both our global ASCEND trial and the Phase 1/2 trial of CR-003 in China are progressing well. We are on track to initiate two more trials during the second half of 2026, with the first ADC combination study for CR-001 and planned clinic entry for CR-002. This continued momentum underscores our commitment to delivering transformative therapies for people living with cancer."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CBIO
Wall Street analysts forecast CBIO stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.960
Low
22.00
Averages
28.20
High
35.00
Current: 16.960
Low
22.00
Averages
28.20
High
35.00
About CBIO
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: On June 25, 2026, Crescent Biopharma approved the grant of 65,100 stock options to three non-executive employees as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness.
- Option Details: The options have an exercise price of $16.99 per share and a 10-year term, with employees able to vest one-fourth of the options on their first anniversary and the remainder vesting monthly thereafter, ensuring continuous service with the company.
- Compliance Assurance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring the company's adherence to regulations in talent acquisition, which bolsters investor confidence.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing innovative therapies including a PD-1 x VEGF bispecific antibody, with the goal of providing potentially transformative treatment options for cancer patients.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: On June 10, 2026, Crescent Biopharma approved the grant of 23,550 stock options to two non-executive employees as equity inducement awards under the 2025 Employment Inducement Incentive Award Plan, aimed at attracting talent and enhancing employee loyalty.
- Option Terms: The options have an exercise price of $17.57 per share and a 10-year term, with one-fourth vesting on the first anniversary of employment and one-forty-eighth vesting monthly thereafter, ensuring continuous service from employees.
- Compliance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), indicating the company's commitment to attracting and retaining key talent while enhancing investor confidence through transparency and adherence to regulations.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing innovative therapies including a PD-1 x VEGF bispecific antibody, with the goal of rapidly developing potentially transformative treatments for a range of solid tumors.
See More
Crescent Biopharma to Present at Upcoming Investor Conferences
- Investor Conference Schedule: Crescent Biopharma is set to present at the Jefferies Global Healthcare Conference on June 3, 2026, at 4:20 p.m. ET in New York, showcasing its latest advancements in cancer treatment.
- Key Conference Dates: Additionally, the company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 8:40 a.m. ET in Miami, further enhancing its market visibility.
- Webcast Availability: Each presentation will be available via live webcast in the Investors section of Crescent Biopharma's website, with replays accessible for 90 days, ensuring investors can stay informed on critical updates.
- Company Vision and Pipeline: Crescent Biopharma aims to become a world-leading oncology company, with a clinical-stage pipeline that includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates, designed to rapidly advance potentially transformative therapies for various solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma approved the grant of 16,950 stock options to two non-executive employees on May 28, 2026, as part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent.
- Option Terms: The options have an exercise price of $21.47 per share and a 10-year term, with one-fourth vesting on the first anniversary of employment and the remainder vesting monthly, ensuring continuous service.
- Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in attracting key talent.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing multiple potentially transformative therapies in clinical development to provide more effective treatment options for cancer patients.
See More
Crescent Biopharma Advances CR-001 Clinical Trial for Solid Tumors
- Trial Launch: Crescent Biopharma is conducting the ASCEND global clinical trial to evaluate CR-001's safety and efficacy in non-small cell lung cancer and other solid tumors, aiming to enroll 290 patients, demonstrating the company's proactive approach in cancer treatment.
- Data Release Expectations: Initial clinical data from the ASCEND trial, including safety, pharmacokinetics, and antitumor activity metrics, are anticipated in Q1 2027, potentially providing critical insights into CR-001's market viability.
- Collaborative Development Plans: The strategic partnership with Sichuan Kelun-Biotech will facilitate CR-001's clinical trials in China, set to commence in H1 2026, indicating the company's intent to expand its global footprint.
- Innovative Drug Design: CR-001, a PD-1 x VEGF bispecific antibody, aims to restore T cells' ability to recognize tumor cells while inhibiting blood supply to tumors, offering new therapeutic options that could transform the treatment landscape for solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: On May 11, 2026, Crescent Biopharma approved the grant of 129,075 stock options to five non-executive employees as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness.
- Option Terms: The options have an exercise price of $18.52 per share and a 10-year term, with one-fourth of the options vesting on the first anniversary of employment and the remainder vesting monthly thereafter, ensuring continuous service from employees.
- Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), indicating the company's commitment to attracting high-quality talent while enhancing transparency and investor confidence.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company by advancing its clinical pipeline, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates, to provide innovative treatment options for cancer patients.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: On June 25, 2026, Crescent Biopharma approved the grant of 65,100 stock options to three non-executive employees as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness.
- Option Details: The options have an exercise price of $16.99 per share and a 10-year term, with employees able to vest one-fourth of the options on their first anniversary and the remainder vesting monthly thereafter, ensuring continuous service with the company.
- Compliance Assurance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring the company's adherence to regulations in talent acquisition, which bolsters investor confidence.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing innovative therapies including a PD-1 x VEGF bispecific antibody, with the goal of providing potentially transformative treatment options for cancer patients.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: On June 10, 2026, Crescent Biopharma approved the grant of 23,550 stock options to two non-executive employees as equity inducement awards under the 2025 Employment Inducement Incentive Award Plan, aimed at attracting talent and enhancing employee loyalty.
- Option Terms: The options have an exercise price of $17.57 per share and a 10-year term, with one-fourth vesting on the first anniversary of employment and one-forty-eighth vesting monthly thereafter, ensuring continuous service from employees.
- Compliance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), indicating the company's commitment to attracting and retaining key talent while enhancing investor confidence through transparency and adherence to regulations.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing innovative therapies including a PD-1 x VEGF bispecific antibody, with the goal of rapidly developing potentially transformative treatments for a range of solid tumors.
See More
Crescent Biopharma to Present at Upcoming Investor Conferences
- Investor Conference Schedule: Crescent Biopharma is set to present at the Jefferies Global Healthcare Conference on June 3, 2026, at 4:20 p.m. ET in New York, showcasing its latest advancements in cancer treatment.
- Key Conference Dates: Additionally, the company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 8:40 a.m. ET in Miami, further enhancing its market visibility.
- Webcast Availability: Each presentation will be available via live webcast in the Investors section of Crescent Biopharma's website, with replays accessible for 90 days, ensuring investors can stay informed on critical updates.
- Company Vision and Pipeline: Crescent Biopharma aims to become a world-leading oncology company, with a clinical-stage pipeline that includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates, designed to rapidly advance potentially transformative therapies for various solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma approved the grant of 16,950 stock options to two non-executive employees on May 28, 2026, as part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent.
- Option Terms: The options have an exercise price of $21.47 per share and a 10-year term, with one-fourth vesting on the first anniversary of employment and the remainder vesting monthly, ensuring continuous service.
- Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in attracting key talent.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing multiple potentially transformative therapies in clinical development to provide more effective treatment options for cancer patients.
See More
Crescent Biopharma Advances CR-001 Clinical Trial for Solid Tumors
- Trial Launch: Crescent Biopharma is conducting the ASCEND global clinical trial to evaluate CR-001's safety and efficacy in non-small cell lung cancer and other solid tumors, aiming to enroll 290 patients, demonstrating the company's proactive approach in cancer treatment.
- Data Release Expectations: Initial clinical data from the ASCEND trial, including safety, pharmacokinetics, and antitumor activity metrics, are anticipated in Q1 2027, potentially providing critical insights into CR-001's market viability.
- Collaborative Development Plans: The strategic partnership with Sichuan Kelun-Biotech will facilitate CR-001's clinical trials in China, set to commence in H1 2026, indicating the company's intent to expand its global footprint.
- Innovative Drug Design: CR-001, a PD-1 x VEGF bispecific antibody, aims to restore T cells' ability to recognize tumor cells while inhibiting blood supply to tumors, offering new therapeutic options that could transform the treatment landscape for solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: On May 11, 2026, Crescent Biopharma approved the grant of 129,075 stock options to five non-executive employees as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness.
- Option Terms: The options have an exercise price of $18.52 per share and a 10-year term, with one-fourth of the options vesting on the first anniversary of employment and the remainder vesting monthly thereafter, ensuring continuous service from employees.
- Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), indicating the company's commitment to attracting high-quality talent while enhancing transparency and investor confidence.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company by advancing its clinical pipeline, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates, to provide innovative treatment options for cancer patients.
See More
